Concepedia

D. Glenn

DG

Statistics

Publications

4

Citations

269

H-Index

4

Active since

2007

Affiliations

Markey Cancer Center(Current)

D. Glenn is an author at Markey Cancer Center specializing in malignant neoplasms, chemotherapy, and pharmacology.

Publications per year

2007–2010

4

Publications

4

Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Sharmila Makhija, Lukas C. Amler, D. Glenn et al. · Journal of Clinical Oncology · 2009 · 187 citations

Medicine, Oncology, Pharmacology +17

Exploratory phase II efficacy study of MORAb-003, a monoclonal antibody against folate receptor alpha, in platinum-sensitive ovarian cancer in first relapse

D. K. Armstrong, Annette Bicher, Robert L. Coleman et al. · Journal of Clinical Oncology · 2008 · 35 citations

Medicine, Oncology, Pharmacology +17

Results from a phase II randomized, placebo-controlled, double-blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer

Sharmila Makhija, D. Glenn, F. Ueland et al. · Journal of Clinical Oncology · 2007 · 24 citations

Medicine, Oncology, Pharmacology +17

Efficacy and safety of farletuzumab, a humanized monoclonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: Final data from a multicenter phase II study.

A. J. White, Robert L. Coleman, D. K. Armstrong et al. · Journal of Clinical Oncology · 2010 · 23 citations

Medicine, Oncology, Pharmacology +16

1–4 of 4